Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenshuikang
- Development stage
- Unknown
- Lead developer
- Buchang Pharmaceuticals
- Administration
- Oral
01
Overview
Shenshuikang is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of chronic renal failure (CRF) and chronic kidney disease (CKD). It is typically composed of several herbal ingredients, including *Rheum palmatum* (Rhubarb), *Astragalus membranaceus*, *Salvia miltiorrhiza*, *Paeonia lactiflora*, and *Carthamus tinctorius*. The mechanism of action involves reducing nitrogenous waste (such as urea nitrogen and creatinine), improving renal blood flow, and exerting anti-inflammatory and anti-fibrotic effects on kidney tissue. It is often prescribed to patients with spleen and kidney yang deficiency accompanied by damp-heat and blood stasis. The drug is approved in China and is manufactured by several companies, most notably Shaanxi Buchang Pharmaceuticals.
- Brand names
- Shenshuikang肾衰康
- Other names
- Shenshuikang CapsuleShenshuikang JiaonangShenshuikang MixtureShenshuikang Heji
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))TGFB1 (Transforming growth factor Beta-1 proprotein)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Shenshuikang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenshuikang.